A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths. The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year. In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps. But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels. |
Pupils welcome new semester with lively activities in N China's HohhotKim Kardashian's daughter North West, 10, styles HERSELF in diamonds galore for fun atChina's logistics industry reports steady growth in 2023China's express delivery sector sees doubleFarmers busy with harvesting, processing spring tea in SW China's GuizhouNumber of Nanjing Massacre survivors down to 36Italy's fashion brands have Chinese connectionTaiwan students can apply for mainland universities from March 1Canadian business council urges regular dialogue with ChinaPolish opponents of abortion march against recent steps to liberalize strict law